Skip to main content

Research Repository

Advanced Search

Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors

Makos, Anaïs; Kuiper, JH; Kehoe, Oksana; Amarasena, R.

Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors Thumbnail


Authors

Anaïs Makos

R. Amarasena



Abstract

Psoriatic arthritis (PsA) is a chronic and painful inflammatory immune-mediated disease. It affects up to 40% of people with psoriasis and it is associated with several comorbidities such as obesity, diabetes, metabolic syndrome and hypertension. PsA is difficult to diagnose because of its diverse symptoms, namely axial and peripheral arthritis, enthesitis, dactylitis, skin changes and nail dystrophy. Different drugs exist to treat the inflammation and pain. When patients do not respond to conventional drugs, they are treated with biologic drugs. Tumor Necrosis Factor inhibitors (TNFi’s) are commonly given as the first biologic drug but beside being expensive they also lack efficacy in 50% of patients. A biomarker predicting individual patient’s response to TNFi would help treating them earlier with an appropriate biologic drug. This study aimed to review the literature to identify potential biomarkers that should be investigated for their predictive ability. Several such biomarkers were identified, namely transmembrane TNFa (tmTNF) Human Serum Albumin (HSA) and its half-life receptor, the neonatal Fc receptor (FcRn) which is also involved in IgG lifespan; calprotectin, High Mobility Group Protein B1 (HMGB1) and Advanced Glycation Endproducts (AGEs) whose overexpression lead to excessive production of pro-inflammatory cytokines; lymphotoxin a (LTa) which induces inflammation by binding to TNF receptor (TNFR); and T helper 17 (Th17) cells which induce inflammation by IL-17A secretion.

Citation

Makos, A., Kuiper, J., Kehoe, O., & Amarasena, R. (2022). Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors. Inflammopharmacology, 77-87. https://doi.org/10.1007/s10787-022-01092-x

Journal Article Type Article
Acceptance Date Oct 18, 2022
Publication Date Dec 12, 2022
Publicly Available Date May 30, 2023
Journal Inflammopharmacology
Print ISSN 0925-4692
Publisher Springer Verlag
Pages 77-87
DOI https://doi.org/10.1007/s10787-022-01092-x
Keywords Psoriatic arthritis; Biologics; Tumor necrosis factor inhibitor; Biomarkers; Resistance
Publisher URL https://link.springer.com/article/10.1007/s10787-022-01092-x
Additional Information This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Files





You might also like



Downloadable Citations